Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04170985
Other study ID # Neuro-R001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 18, 2019
Est. completion date January 31, 2024

Study information

Verified date April 2024
Source Illumina, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enrollment.


Description:

This is a prospective, randomized study to evaluate the diagnostic yield of SOC compared to cWGS in each participant. Throughout this study, each participant will receive SOC testing as determined by the site clinical team. After the physician orders SOC testing during standard clinical practice, the subject will be introduced and invited to participate in the study. On Day 180, the participant will receive a cWGS result and the participant will continue to be followed for an additional 180 days. A blood sample from each enrolled participant will be collected and shipped to the Illumina Clinical Services Laboratory ("ICSL"), which is Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited. ICSL will conduct cWGS testing with the TruGenome Undiagnosed Disease Test ("TruGenome Test"). The TruGenome Test cWGS results will be provided to the Principal Investigator (PI) or designee who will evaluate each participant's test outcome based on aggregate medical information.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years at the time of consent 2. Participant is referred to a Neurogenetics Program due to suspected genetic etiology of a neurological syndrome 3. No history of prior genetic testing for the suspected condition in the participant or any family member with a similar phenotype 4. Must be able to have one - 4 to 6 ml tube of whole blood drawn for testing 5. Able to provide written consent. If participant unable to do so, a legally authorized representative (LAR) must do so on behalf of the participant Exclusion Criteria: 1. Any known non-genetic cause(s) of disease, disorder, or phenotypic defect 2. Eligibility for enrollment of each participant is at the discretion of the site PI 3. Patient is unable or unwilling to undergo any form(s) of SOC genetic testing 4. SOC testing is NOT requested for the participant

Study Design


Intervention

Other:
clinical Whole Genome Sequencing
Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.

Locations

Country Name City State
United States Univ. of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Illumina, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Time to Diagnosis between cWGS and SOC testing Average time (in days) to diagnosis between SOC and cWGS testing (duration between when sample is approved and when result(s) is/are delivered) Day 0 - Day 365
Other Clinical Survey by the clinician who ordered SOC testing Clinician and genetic counselor satisfaction measured by an end-of-study questionnaire determining the overall satisfaction with the use of cWGS testing Day 365
Other Participant Survey Participant satisfaction measured by an end-of-study questionnaire determining the overall satisfaction with the use of cWGS testing Participant satisfaction measured by an end-of-study questionnaire determining the participant's overall satisfaction with the use of cWGS testing Day 365
Primary Diagnostic Yield between cWGS and SOC testing The number of participants who have a diagnosis in the SOC arm vs the cWGS arm as measured by the test outcome Day 0 - Day 365
Secondary Change of Management between cWGS and SOC testing as measured by a management questionnaire collected on a case report form The number of participants who have a change in management after receiving SOC results vs cWGS results as measured by a management questionnaire at baseline, Day 180 and Day 365 Day 0 - Day 365
Secondary Resource Utilization between cWGS and SOC testing The number of participants who have utilized resources to include specialist referrals, tests/procedures ordered and procedures avoided in the SOC arm vs the cWGS arm as measured by data collection case report forms Day 0 - Day 365
Secondary Quality of Life between cWGS and SOC testing Comparison between Quality-of-Life scores as measured by the 12-Item Short Form Survey (SF12) from baseline compared to end of study Day 0 - Day 365
Secondary Diagnostic Accuracy between cWGS and SOC testing when comparing the medical monitor test outcome and the site PI test outcome Diagnostic accuracy- percent positive agreement between test outcome classified by the medical monitor and the site PI or designee Day 0 - Day 180
Secondary Diagnostic Yield within Cohort when evaluating specific Neurologic disorders Difference in diagnostic yield between cohorts of neurological disorders Day 0 - Day 365
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05519592 - Proximal Lower Limb Intramuscular Block : Effects on Hemiparetic Gait N/A
Recruiting NCT04098679 - Childhood Adiposity and Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes (CONCEPTT Kids)
Completed NCT03946137 - Chest Therapy and Postural Education in Children With Cerebral Palsy N/A
Completed NCT05217186 - Associations Between Early Neonatal Neuroimaging, Hammersmith Infant Neurological Examination and General Movements
Not yet recruiting NCT05506306 - Multitissular Effect of Vertical Mobilization Using the Exoskeleton AtalanteTM in Neurological Chair- or Bed-bound Patients
Recruiting NCT04846413 - Voice Analysis in Patients With Neurologic Diseases
Recruiting NCT05260190 - Manual Dexterity Modifications After Application of tSMS Over the Primary Motor Cortex (M1) N/A
Not yet recruiting NCT04906681 - Implementation of a Rehabilitation Technology in Orthopedic and Neurological Rehabilitation to Increase Therapy Dosage: an Exploratory Study Phase 1/Phase 2
Completed NCT04743037 - Interactive Self-Management Augmented by Rehabilitation Technologies N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Recruiting NCT05132517 - Magnesium and Cognition After Stroke
Recruiting NCT04100993 - Multisystem and Autonomic Complications of NMD on Long-term NIV
Recruiting NCT05652946 - IISART (International Industry Society of Advanced Rehabilitation Technology) Advanced Rehabilitation Technology Study N/A
Recruiting NCT06146543 - Stress Ball During Lumbar Puncture the Effect of the Application on Anxiety Level N/A
Completed NCT06368024 - Establishment of Delphi-MD Safety Performance and Reliability
Not yet recruiting NCT06169696 - EMPOWER Early Feasibility Study: Non-invasive BCI to Control a Wheelchair for People With Paralysis N/A
Completed NCT03329872 - Neuro-Orthopedic Registry of the University Hospital of Toulouse
Completed NCT05483244 - Weaning Success in Different Weaning Strategies in Early Neurological Rehabilitation Patients - a Matched-pair Analysis
Completed NCT04624347 - NEOVIDEO : Impact of Monitoring Motor Activity by Video Analysis on the Sleep of Very Preterm Infants N/A